Diversity and origin of hepatitis C virus infection among unpaid blood donors in the Netherlands

Transfusion

Volumn 46, Issue 10, 2006, Pages 1719-1728

  Van De Laar, Thijs J W ^a   Koppelman, Marco H G M ^b   Van Der Bij, Akke K ^b   Zaaijer, Hans L ^b   Cuijpers, H Theo M ^b   Van Der Poel, Cees L ^b   Coutinho, Roel A ^b   Bruisten, Sylvia M ^b  

^a Amsterdam Health Service   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CALCULATION; EPIDEMIC; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HUMAN; HUMAN CELL; IMMIGRANT; INCIDENCE; INFECTION RISK; INTERVIEW; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; NETHERLANDS; NUCLEOTIDE SEQUENCE; POLICY; PREVALENCE; QUESTIONNAIRE; RISK FACTOR; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS TRANSMISSION;

ADULT; BLOOD DONORS; BLOOD TRANSFUSION; EPIDEMIOLOGY, MOLECULAR; FEMALE; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33748930666     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00961.x     Document Type: Article

References (47)

1. Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997;277:967-72.
2. van den Burg PJ, Vrielink H, Reesink HW. Donor selection: the exclusion of high risk donors? Vox Sang 1998;74(Suppl 2):499-502.
3. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
4. Jauncey M, Micallef JM, Gilmour S, et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004;190:1270-4.
5. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
6. Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatol 1999;31(Suppl 1):80-3.
7. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.
8. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002;2:293-302.
9. Forns X, Martinez-Bauer E, Feliu A, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology 2005;41:115-22.
10. Macedo de Oliveira A, White KL, Leschinsky DP, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med 2005;142:898-902.
11. van de Laar TJ, Langendam MW, Bruisten SM, et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol 2005;77:509-18.
12. Kretzschmar M. De prevalentie van hepatitis C in Nederland [in Dutch]. Bilthoven RIVM internal report project V/210041. 2004. p. 1-13. http://www.RIVM.nl.
13. Plug I, van der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004;104:3494-500.
14. Schneeberger PM, Keur I, van Loon AM, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis 2000;182:1291-9.
15. World Health Organisation. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 1999;74:425-7.
16. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73.
17. Schroter M, Zollner B, Laufs R, et al. Changes in the prevalence of hepatitis C virus genotype among injection drug users: a highly dynamic process. J Infect Dis 2004;190:1199-200.
18. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000;13:223-35.
19. van Steenbergen JE, Tjon G, van den Hoek A, et al. Two years' prospective collection of molecular and epidemiological data shows limited spread of hepatitis A virus outside risk groups in Amsterdam, 2000-2002. J Infect Dis 2004;189:471-82.
20. Nakano T, Lu L, Liu P, et al. Viral gene sequences reveal the variable history of hepatitis C virus infection among countries. J Infect Dis 2004;190:1098-108.
21. Koppelman MH, Zaaijer HL. Diversity and origin of hepatitis B virus in Dutch blood donors. J Med Virol 2004;73:29-32.
22. van Asten L, Verhaest I, Lamzira S, et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis 2004;189:292-302.
23. Cochrane A, Searle B, Hardie A, et al. A genetic analysis of hepatitis C virus transmission between injection drug users. J Infect Dis 2002;186:1212-21.
24. Dal Molin G, Ansaldi F, Biagi C, et al. Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J Med Virol 2002;68:352-6.
25. Elghouzzi MH, Bouchardeau F, Pillonel J, et al. Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors. Vox Sang 2000;79:138-44.
26. Gerard C, Delwaide J, Vaira D, et al. Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium. J Med Virol 2005;76:503-10.
27. Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005;12:405-13.
28. Jongerius JM, Sjerps M, Cuijpers HT, et al. Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening. Transfusion 2002;42:792-7.
29. Busch MP. Closing the window on viral transmission in blood transfusion. In: Stramer SL, editor. Blood safety in the new millennium. Bethesda: American Associaton of Blood Banks; 2001. pp. 33-54.
30. Orton SL, Stramer SL, Dodd RY, et al. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion 2004;44:275-81.
31. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002;36:S93-S98.
32. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999;41:95-8.
33. Alvarez M, Oyonarte S, Rodriguez PM, et al. Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion 2002;42:994-8.
34. Offergeld R, Faensen D, Ritter S, et al. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-02: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 2005;10:8-11.
35. Chiavetta JA, Escobar M, Newman A, et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 2003;169:767-73.
36. Pillonel J, Laperche S, Saura C, et al. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion 2002;42:980-8.
37. Pillonel J, Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005;10:5-8.
38. Soldan K, Barbara JA, Ramsay ME, et al. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang 2003;84:274-86.
39. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
40. Sharma UK, Schreiber GB, Glynn SA, et al. Knowledge of HIV/AIDS transmission and screening in United States blood donors. Transfusion 2001;41:1341-50.
41. Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005;76:327-32.
42. Prati D, Capelli C, Silvani C, et al. The incidence and risk factors of community-acquired hepatitis C in a cohort of Italian blood donors. Hepatology 1997;25:702-4.
43. Ross RS, Viazov S, Renzing-Kohler K, et al. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J Med Virol 2000;60:122-5.
44. Schroter M, Zollner B, Schafer P, et al. Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol 2002;40:1866-8.
45. Smith DB, Pathirana S, Davidson F, et al. The origin of hepatitis C virus genotypes. J Gen Virol 1997;78:321-8.
46. Pybus OG, Cochrane A, Holmes EC, et al. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol 2005;5:131-9.
47. Choo QL, Richman KH, Han H, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 1991;88:2451-5.